Jennifer L. Taubert is Executive Vice President and Worldwide Chairman, Innovative Medicine at Johnson & Johnson, the world’s largest healthcare company. She is a member of the Corporation’s Executive Committee and leads the Innovative Medicine Group Operating Committee.

As Executive Vice President, Pharmaceuticals, R&D and Johnson & Johnson (J&J) Executive Committee member, John’s mission is to focus the best research and development teams in the world at the intersection of unmet medical need and innovation to change the trajectory of human health. A biomedical research leader with a distinguished career across nonprofit, academia, and industry, John encourages a culture that is fast-paced and open to reimagining how life-saving medicines and vaccines are discovered, developed and delivered. Employing multiple drug modalities, John’s team works across a wide range of focus areas, including: Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension and Specialty Ophthalmology.

Dapo Ajayi is Vice President, Supply Chain at Johnson & Johnson Innovative Medicine. In this role, Dapo is responsible for the global, end-to-end manufacturing and supply management of J&J pharmaceutical brands. She is a member of the Pharmaceutical Group Operating Committee (GOC) and the Supply Chain Management Committee (SCMC).

Paul Anthony is Human Resources (HR) Head of Global Pharmaceuticals & External Innovation at Johnson & Johnson Innovative Medicine. Paul serves as a member of Johnson & Johnson’s Human Resource Executive Leadership Team, the Pharmaceutical Group Operating Committee and the R&D Management Committee. Paul leads HR strategy and operational excellence for the Pharmaceutical sector and Johnson & Johnson Innovation, including the Innovation Centers, JLABS, JJDC, the cross-sector Lung Cancer Initiative and Global Public Health.

Sarah Brennan is Company Group Chairman, Global Commercial Strategy Organization, for Johnson & Johnson Innovative Medicine.

Tom Cavanaugh is Company Group Chairman, North America. He is a member of the Innovative Medicine Pharmaceuticals Group Operating Committee and is responsible for leading our efforts to transform the health of people in the U.S. and Canada who face a range of common and rare, complex diseases across our areas of focus.

Federico Feldstein is the Vice President and Chief Quality Officer of Innovative Medicine at Johnson & Johnson. In his current role, Federico leads the Innovative Medicine Quality Leadership Team in setting the quality strategy and the quality processes and systems to strengthen our quality and compliance profile and leadership position in the pharmaceutical industry. He is a member of the Johnson & Johnson Quality & Compliance Leadership Team as well as the Innovative Medicine Group Operating Committee (GOC).

David M. Lee, M.D., Ph.D., is Global Focus Area Head, Immunology, where he leads a team focused on end-to-end pipeline and a portfolio of treatments for immune-mediated disease. Under his leadership, Immunology researchers are working to build on the success of our current portfolio, which includes STELARA® (ustekinumab) and TREMFYA® (guselkumab).

Joyce Lee is the Chief Information Officer (CIO), Pharmaceuticals. Joyce also serves on the Pharmaceuticals Group Operating Committee (GOC).

Bill Martin is the Global focus area head, Neuroscience, and is a member of the company’s Group Operating Committee. He leads a dedicated team focused on the discovery and development of a precision neuroscience pipeline of transformative treatments for individuals grappling with serious neuropsychiatric and neurodegenerative disorders. Building on Johnson & Johnson’s nearly seven-decade legacy in neuroscience, Bill’s team is driving a differentiated portfolio of new and innovative therapies, each targeting a subpopulation of patients.

Deidre Meehan is Worldwide Vice President, General Counsel, Pharmaceuticals. Deidre serves on the Law Department Legal Leadership Team and manages the Pharmaceuticals Legal Group globally. Deidre is also a member of the Pharmaceuticals Group Operating Committee. In her role, Deidre continues to build on her years of experience as a trusted strategic partner and legal leader on Enterprise-wide regulatory matters and continues her strong focus on shaping the external environment to accelerate innovation for patients.

Nauman Shah leads a global team charged with driving business development strategy and pursuing transformational acquisitions, licensing, and partnership opportunities to advance Johnson & Johnson’s mission to save and improve lives.

Working closely with the external biotech innovation ecosystem and financial community, Nauman helps evolve Johnson & Johnson’s strategic portfolio by identifying and sourcing external innovation opportunities to accelerate positive patient impact and create value for the company. A member of the Innovative Medicine Group Operating Committee, Nauman has extensive experience successfully activating engagement, collaboration, and talent development across large, cross-functional teams.


Nauman joined Johnson & Johnson in 2003 and has since held various leadership positions in marketing and Enterprise operations. He previously led Johnson & Johnson MedTech’s Strategic Customer team to launch value-based care programs that enhance operational efficiency for healthcare systems. Formerly the Chief of Staff to the former Chairman and CEO, Nauman was directly involved in the company’s strategic planning process and executing enterprise growth initiatives. Notably during his tenure in marketing, he led the launches of multiple new products, including: TOPAMAX, XARELTO, and INVOKANA. Throughout his career, Nauman has championed initiatives that advance new capabilities and enable greater collaboration – all aimed at delivering on Johnson & Johnson’s mission to profoundly improve health for humanity.


Prior to joining Johnson & Johnson, Nauman worked at Pfizer/Pharmacia, where he played a significant role in successfully launching three major products in urology, arthritis, and pain. He holds a Bachelor of Arts degree in Biological Basis of Behavior from the University of Pennsylvania and a Master of Business Administration in Finance from Temple University. He graduated from the Wharton School of the University of Pennsylvania after completing the General Management Program.

Darren Snellgrove is Vice President, Group Finance, Worldwide Pharmaceuticals. In this position, Darren will provide strategic and financial leadership to the Global Pharmaceuticals Group and partner with the Group Operating Company to further drive above-market growth with transformational medical innovation that yields successful business outcomes for the sector and enterprise.

Since starting his career at Johnson & Johnson in Belgium almost 30 years ago, Kris Sterkens has been part of many teams across EMEA, Asia Pacific, and the United States.

Richard Tillyer, Ph.D, is Global Head, Discovery , Product Development, and Supply at Johnson & Johnson Innovative Medicine. In this role, he leads an integrated discovery and manufacturing sciences organization that comprises all modalities including small molecules, traditional and non-traditional single molecule biologics, and larger, more complex multicomponent biologics including RNA, viruses and cells.

Cyril Titeux is Company Group Chairman, Johnson & Johnson Innovative Medicine Asia Pacific, and a member of the Innovative Medicine Group Operating Committee (GOC).

Sandra (Sandy) Waite is Global Leader, Pharmaceuticals Communications & Public Affairs. In this role, Sandy leads our global communication and public affairs strategy across our worldwide Johnson & Johnson Innovative Medicine organization.